We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why Gilead Sciences (GILD) Dipped More Than Broader Market Today
Read MoreHide Full Article
In the latest trading session, Gilead Sciences (GILD - Free Report) closed at $134.25, marking a -1.92% move from the previous day. This move lagged the S&P 500's daily loss of 1.67%. On the other hand, the Dow registered a loss of 1.73%, and the technology-centric Nasdaq decreased by 2.15%.
Shares of the HIV and hepatitis C drugmaker witnessed a loss of 4.79% over the previous month, beating the performance of the Medical sector with its loss of 7.36%, and the S&P 500's loss of 6.15%.
The investment community will be paying close attention to the earnings performance of Gilead Sciences in its upcoming release. On that day, Gilead Sciences is projected to report earnings of $1.86 per share, which would represent year-over-year growth of 2.76%. Meanwhile, the latest consensus estimate predicts the revenue to be $6.86 billion, indicating a 2.93% increase compared to the same quarter of the previous year.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $8.66 per share and a revenue of $30.18 billion, indicating changes of +6.26% and +2.5%, respectively, from the former year.
Investors should also take note of any recent adjustments to analyst estimates for Gilead Sciences. Recent revisions tend to reflect the latest near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. Gilead Sciences is currently a Zacks Rank #3 (Hold).
In the context of valuation, Gilead Sciences is at present trading with a Forward P/E ratio of 15.81. For comparison, its industry has an average Forward P/E of 17.76, which means Gilead Sciences is trading at a discount to the group.
We can additionally observe that GILD currently boasts a PEG ratio of 1.79. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. The Medical - Biomedical and Genetics industry had an average PEG ratio of 1.52 as trading concluded yesterday.
The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 148, positioning it in the bottom 40% of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Why Gilead Sciences (GILD) Dipped More Than Broader Market Today
In the latest trading session, Gilead Sciences (GILD - Free Report) closed at $134.25, marking a -1.92% move from the previous day. This move lagged the S&P 500's daily loss of 1.67%. On the other hand, the Dow registered a loss of 1.73%, and the technology-centric Nasdaq decreased by 2.15%.
Shares of the HIV and hepatitis C drugmaker witnessed a loss of 4.79% over the previous month, beating the performance of the Medical sector with its loss of 7.36%, and the S&P 500's loss of 6.15%.
The investment community will be paying close attention to the earnings performance of Gilead Sciences in its upcoming release. On that day, Gilead Sciences is projected to report earnings of $1.86 per share, which would represent year-over-year growth of 2.76%. Meanwhile, the latest consensus estimate predicts the revenue to be $6.86 billion, indicating a 2.93% increase compared to the same quarter of the previous year.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $8.66 per share and a revenue of $30.18 billion, indicating changes of +6.26% and +2.5%, respectively, from the former year.
Investors should also take note of any recent adjustments to analyst estimates for Gilead Sciences. Recent revisions tend to reflect the latest near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. Gilead Sciences is currently a Zacks Rank #3 (Hold).
In the context of valuation, Gilead Sciences is at present trading with a Forward P/E ratio of 15.81. For comparison, its industry has an average Forward P/E of 17.76, which means Gilead Sciences is trading at a discount to the group.
We can additionally observe that GILD currently boasts a PEG ratio of 1.79. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. The Medical - Biomedical and Genetics industry had an average PEG ratio of 1.52 as trading concluded yesterday.
The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 148, positioning it in the bottom 40% of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.